Dear reader, We are excited to announce … The United States Food and Drug Administration (FDA)... has granted Cardiol Therapeutics Inc. Orphan Drug Designation (“ODD”). This is a status given to certain drugs called “orphan drugs”, which show promise in the treatment, prevention, or diagnosis of orphan diseases. An orphan disease is a rare disease or condition that affects fewer than 200,000 people in the United States. The only FDA-approved therapy for recurrent pericarditis, launched in 2021, is costly and is primarily used as a third-line intervention. So, this is Good News for Cardiol Therapeutics. This designation allows them to continue working on improving the lives of patients suffering with recurrent pericarditis, a debilitating heart disease associated with symptoms that adversely affect quality of life and physical activity. And it's Great News for investors because… Once the US FDA grants orphan drug designation to a drug, that company has the potential of getting seven years of marketing exclusivity. This exclusivity can give the company a competitive advantage, preventing other generic treatments from entering the market, and help ensure that it can recoup its research and development costs. But that’s not all… The orphan designation appears to be successful at generating positive value for companies, as seen by the positive and significant average increases in stock price. Get more info about Cardiol Therapeutics Inc. here. Tips4Traders | 
No comments:
Post a Comment